Abstract

OBJECTIVE

This study examined the correlation between cerebral blood volume (CBV) and MET PET.

SUBJECTS AND METHODS

108 non-contrast-enhanced gliomas (41.8±12.3 years old, 58 males) examined between April 2012 and December 2022 were included. The pathological diagnosis was Glioblastoma, IDH-wildtype (G): 21 cases, Astrocytoma, IDH-mutant (A): 52, Oligodendroglioma, IDH-mutant and 1p/19q codeleted (O): 35. T2 region (the high signal region on T2WI) on MRI and high-MET region (tumor maximum SUV/normal frontal cortex SUV (T/N) ratio > 1.3) on MET PET were defined. The rCBV (regional mean CBV/normal white matter mean CBV) was calculated using dynamic-susceptibility-contrast perfusion MRI to compare each region.

RESULT

The rCBV (3.22±0.95) in the T2 region in 67 patients with MET accumulation was significantly higher than those (2.47±0.64) in 41 patients without MET accumulation (p<0.0001). The cutoff rCBV value obtained from the ROC curve for MET accumulation was 2.79, with a sensitivity of 61.2%, specificity of 75.6%, and AUC of 0.73. The rCBV in the T2 region was (G: 3.60±1.0 A: 2.53±0.69 O: 3.14±0.89) significantly higher in group G (p<0.0001). In the 69 patients with MET accumulation (G: 16, A: 21, O: 30), the rCBV was 3.23±0.96 in the T2 region and 3.48±1.13 in the high-MET region, significantly higher in the latter (p<0.0016). The rCBV was significantly higher in the group G both in the T2 region (G: 3.82±0.97 A: 2.77±0.68 O: 3.22±0.93, p=0.0026) and in the high-MET region (G: 4.12±1.18 A: 3.29±1.0 O: 3.27±1.1, p=0.031). The difference was most in the group A (p=0.016). The rCBV significantly correlated with T/N ratio in both the T2 region (r=0.41, p=0.0005) and the high-MET region (r=0.49, p<0.0001), mainly observed in groups A and O.

DISCUSSION

The rCBV and MET accumulation correlated in non-contrast-enhanced gliomas. The CBV may be an alternative to MET PET in imaging gliomas.

This content is only available as a PDF.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact [email protected].